OnKure CFO Executes Small RSU-Related Sale; H.C. Wainwright Lowers Target to $27
On March 23, 2026, OnKure Therapeutics CFO Jason A. Leverone sold 301 shares of Class A common stock at a weighted average price of $4.1565 to satisfy tax withholding tied to vested restricted stock units. The transaction, disclosed on a Form 4 filing, generated $1,251 in proceeds and followed a share price range of $3.995 to $4.235. Separately, H.…